Aura Biosciences Inc at Bank of America Healthcare Conference Transcript
Joining us on this webcast. I am Tazeen Ahmad. I'm one of the senior SMid biotech analysts here at Bank of America. It's our pleasure to have our next presenting company at our BofA Healthcare Conference presenting, Aura Biosciences. And presenting for Aura is Chief Executive Officer, Elisabet de los Pinos. Elisabet, I'm going to turn it over to you to go over the slides.
Thank you. It's a pleasure to be here. I'm the CEO, Elisabet de los Pinos, at Aura Biosciences. So let me introduce you to our company. We're a clinical-stage oncology company developing a novel class of drugs that we call virus-like drug conjugates. Initially, we focused our clinical development in ocular oncology, which is a group of rare diseases, cancers that start in the eye and is a very high unmet medical need because these patients have no drugs approved, and they're basically treated with radiotherapy,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |